Perspective clinical application of modern anti-fibrotic therapies in dacryology
Реин Д. А., Ат'Кова Е. Л., Раменская Г. В., Ярцев В. Д., Роот А. О., Жуков О. В.
Экспериментальная и клиническая фармакология
Т. 81, Вып. 6, С. 35-39
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.30906/0869-2092-2018-81-6-35-39
Аннотация:
The main reason of surgical treatment failure in cases of chronic dacryocystitis concurrent with nasolacrimal duct obliteration is scarring of the newly created ostium. This outcome is caused by the continued activity of myofibroblasts that leads to the formation of a rough scar. Mitomycin C is currently considered to be the most preferred anti-fibrotic drug. Nonetheless, contradictory evidence of the drug efficiency stimulates further research for finding alternative anti-fibro-tic therapeutics. Recently, several advances were made in developing new anti-fibrotic drugs, including monoclonal antibodies, small RNA molecules, and other gene therapy formulations, nanoparticles and small-molecule therapeutics. This review article aims to provide up-to-date information on the efficacy of mentioned agents and on prospects of their use in dacryology. © 2018 Izdatel'stvo Meditsina. All rights reserved.
Ключевые слова:
Anti-fibrotic therapy; Dacryocystorhinostomy; Dacryology; Dacryostomy; Fibrosis; Mitomycin C; Scarring
antifibrotic agent; Article; dacryocystitis
Язык текста: Русский
ISSN: 0869-2092
Реин Д. А.
Ат'Кова Е. Л.
Раменская Г. В. Галина Владиславовна 1972-
Ярцев В. Д.
Роот А. О.
Жуков О. В.
Rein D. A.
At'Kova E. L.
Ramenskaya G. V. Galina Vladislavovna 1972-
Yartsev V. D.
Root A. O.
Zhukov O. V.
Perspective clinical application of modern anti-fibrotic therapies in dacryology
Текст визуальный непосредственный
Экспериментальная и клиническая фармакология
ООО "Фолиум"
Т. 81, Вып. 6 С. 35-39
2018
Статья
Anti-fibrotic therapy Dacryocystorhinostomy Dacryology Dacryostomy Fibrosis Mitomycin C Scarring
antifibrotic agent Article dacryocystitis
The main reason of surgical treatment failure in cases of chronic dacryocystitis concurrent with nasolacrimal duct obliteration is scarring of the newly created ostium. This outcome is caused by the continued activity of myofibroblasts that leads to the formation of a rough scar. Mitomycin C is currently considered to be the most preferred anti-fibrotic drug. Nonetheless, contradictory evidence of the drug efficiency stimulates further research for finding alternative anti-fibro-tic therapeutics. Recently, several advances were made in developing new anti-fibrotic drugs, including monoclonal antibodies, small RNA molecules, and other gene therapy formulations, nanoparticles and small-molecule therapeutics. This review article aims to provide up-to-date information on the efficacy of mentioned agents and on prospects of their use in dacryology. © 2018 Izdatel'stvo Meditsina. All rights reserved.